[L04AA27, fingolimod, Lanreotide may increase the bradycardic activities of Fingolimod.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Lanreotide.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Lanreotide.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Lanreotide.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Lanreotide.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Lanreotide.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Lanreotide.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Lanreotide.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Tetracaine.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Lanreotide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Lanreotide.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Lanreotide.]
[S01ED01, timolol, Timolol may increase the bradycardic activities of Lanreotide.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Lanreotide.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lanreotide.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Lanreotide.]
[A03AA05, trimebutine, Lanreotide may increase the bradycardic activities of Trimebutine.]
[N03AC02, trimethadione, Trimethadione may increase the bradycardic activities of Lanreotide.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Lanreotide.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Lanreotide.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lanreotide.]
[C08DA01, verapamil, Verapamil may increase the bradycardic activities of Lanreotide.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Lanreotide.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Lanreotide.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Lanreotide.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Lanreotide.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Lanreotide.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Lanreotide.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Lanreotide.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Lanreotide.]
[N05AE04, ziprasidone, The metabolism of Ziprasidone can be decreased when combined with Lanreotide.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Lanreotide.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Lanreotide.]
[C07AB03, atenolol, Atenolol may increase the bradycardic activities of Lanreotide.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Lanreotide.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Lanreotide.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Lanreotide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Lanreotide.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Lanreotide.]
[C08CA13, lercanidipine, Lercanidipine may increase the bradycardic activities of Lanreotide.]
[N06DA02, donepezil, Donepezil may increase the bradycardic activities of Lanreotide.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Lanreotide.]
[H01CB05, pasireotide, The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Lanreotide.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Lanreotide.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Lanreotide.]
[C04AX11, bencyclane, Lanreotide may increase the bradycardic activities of Bencyclane.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Lanreotide.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the bradycardic activities of Lanreotide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Lanreotide.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin detemir.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Lanreotide.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Lanreotide.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be decreased when combined with Lanreotide.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Levomilnacipran.]
[C08EA02, bepridil, Bepridil may increase the bradycardic activities of Lanreotide.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Lanreotide.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Lanreotide.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lanreotide.]
[C07AB04, acebutolol, Acebutolol may increase the bradycardic activities of Lanreotide.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Lanreotide.]
[S01ED02, betaxolol, Betaxolol may increase the bradycardic activities of Lanreotide.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Lanreotide.]
[L01ED02, ceritinib, Lanreotide may increase the bradycardic activities of Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Lanreotide.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Lanreotide.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Lanreotide.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Lanreotide.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Lanreotide.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lanreotide.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Lanreotide.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Lanreotide.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Lanreotide.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Lanreotide.]
[C01EB17, ivabradine, Lanreotide may increase the bradycardic activities of Ivabradine.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Lanreotide.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Lanreotide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin degludec.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Lanreotide.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be decreased when combined with Lanreotide.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Lanreotide.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Lanreotide.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Lanreotide.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Lanreotide.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Lanreotide.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lanreotide.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Lanreotide.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Lanreotide.]
[N04BC01, bromocriptine, The serum concentration of Bromocriptine can be increased when it is combined with Lanreotide.]
[C08CA01, amlodipine, Amlodipine may increase the bradycardic activities of Lanreotide.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Lanreotide.]
[V10XX04, lutetium Lu 177 dotatate, The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Lanreotide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Bupivacaine.]
[C07AA19, bupranolol, Lanreotide may increase the bradycardic activities of Bupranolol.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Lanreotide.]
[N06DA03, rivastigmine, Rivastigmine may increase the bradycardic activities of Lanreotide.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be decreased when combined with Lanreotide.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Lanreotide.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Lanreotide.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Lanreotide.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Oxybuprocaine.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Lanreotide.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Lanreotide.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Lanreotide.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Lanreotide.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Lanreotide.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Lanreotide.]
[C07AB07, bisoprolol, Bisoprolol may increase the bradycardic activities of Lanreotide.]
[C07AA17, bopindolol, Lanreotide may increase the bradycardic activities of Bopindolol.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Lanreotide.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Lanreotide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Lanreotide.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Lanreotide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Lanreotide.]
[C07AG02, carvedilol, Carvedilol may increase the bradycardic activities of Lanreotide.]
[C07AB08, celiprolol, Celiprolol may increase the bradycardic activities of Lanreotide.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be decreased when combined with Lanreotide.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Lanreotide.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Lanreotide.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Lanreotide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Chloroprocaine.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Lanreotide.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Lanreotide.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Cibenzoline.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Lanreotide.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Lanreotide.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Lanreotide.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Ubidecarenone.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Lanreotide.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Lanreotide.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Lanreotide.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Lanreotide.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be decreased when combined with Lanreotide.]
[V09IX09, edotreotide gallium ga-68, Lanreotide may decrease effectiveness of Edotreotide gallium Ga-68 as a diagnostic agent.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin pork.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Lanreotide.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Lanreotide.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Lanreotide.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Lanreotide.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Lanreotide.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Lanreotide.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Lanreotide.]
[S01AE06, gatifloxacin, The risk or severity of hypoglycemia can be increased when Gatifloxacin is combined with Lanreotide.]
[C08CA16, clevidipine, Clevidipine may increase the bradycardic activities of Lanreotide.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Lanreotide.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Dyclonine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Lanreotide.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Lanreotide.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be decreased when combined with Lanreotide.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lanreotide.]
[N06BX18, vinpocetine, Lanreotide may increase the bradycardic activities of Vinpocetine.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Lanreotide.]
[N07CA02, cinnarizine, Cinnarizine may increase the bradycardic activities of Lanreotide.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Lanreotide.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Lanreotide.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Lanreotide.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Lanreotide is combined with Fexinidazole.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lanreotide.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Lanreotide.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Levobupivacaine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Lanreotide.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Lanreotide.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Lanreotide.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Lanreotide.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lanreotide.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Cocaine.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Lanreotide.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Lanreotide.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Lanreotide.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin glargine.]
[H01AX01, pegvisomant, The risk or severity of increased transaminases can be increased when Lanreotide is combined with Pegvisomant.]
[C08CA09, lacidipine, Lanreotide may increase the bradycardic activities of Lacidipine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lanreotide.]
[N03AX09, lamotrigine, Lamotrigine may increase the bradycardic activities of Lanreotide.]
[C08CA11, manidipine, Lanreotide may increase the bradycardic activities of Manidipine.]
[C07AA14, mepindolol, Lanreotide may increase the bradycardic activities of Mepindolol.]
[C04AX01, cyclandelate, Cyclandelate may increase the bradycardic activities of Lanreotide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Lanreotide.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Lanreotide.]
[S01XA18, cyclosporine, The bioavailability of Cyclosporine can be decreased when combined with Lanreotide.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Lanreotide.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Lanreotide.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Lanreotide.]
[C07AB12, nebivolol, Nebivolol may increase the bradycardic activities of Lanreotide.]
[N06AX06, nefazodone, The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Lanreotide.]
[N06AB10, escitalopram, The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Lanreotide.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Lanreotide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Cinchocaine.]
[A03AX04, pinaverium, Lanreotide may increase the bradycardic activities of Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lanreotide.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Lanreotide.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Lanreotide.]
[C08CA03, isradipine, Isradipine may increase the bradycardic activities of Lanreotide.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Lanreotide.]
[C01AA05, digoxin, Digoxin may increase the bradycardic activities of Lanreotide.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Lanreotide.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Lanreotide.]
[J05AE08, atazanavir, The metabolism of Atazanavir can be decreased when combined with Lanreotide.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Pramocaine.]
[C08DB01, diltiazem, Diltiazem may increase the bradycardic activities of Lanreotide.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Diphenhydramine.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Lanreotide.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Lanreotide.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Lanreotide.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Lanreotide.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Lanreotide.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Lanreotide.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Lanreotide.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Lanreotide.]
[C07AB13, talinolol, Lanreotide may increase the bradycardic activities of Talinolol.]
[G04BD05, terodiline, Lanreotide may increase the bradycardic activities of Terodiline.]
[C07AA16, tertatolol, Lanreotide may increase the bradycardic activities of Tertatolol.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Lanreotide.]
[M01AG02, tolfenamic acid, Lanreotide may increase the bradycardic activities of Tolfenamic acid.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Lanreotide.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Lanreotide.]
[C08CA12, mepirodipine, Lanreotide may increase the bradycardic activities of Barnidipine.]
[N03AX15, zonisamide, Zonisamide may increase the bradycardic activities of Lanreotide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Lanreotide.]
[C02AC02, guanfacine, Guanfacine may increase the bradycardic activities of Lanreotide.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Lanreotide.]
[N03AD01, ethosuximide, Ethosuximide may increase the bradycardic activities of Lanreotide.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Lanreotide.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Lanreotide.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Lanreotide.]
[R06AX12, terfenadine, The metabolism of Terfenadine can be decreased when combined with Lanreotide.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Lanreotide.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Lanreotide.]
[C08CA02, felodipine, Felodipine may increase the bradycardic activities of Lanreotide.]
[C08EA01, fendiline, Lanreotide may increase the bradycardic activities of Fendiline.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Lanreotide.]
[N07CA03, flunarizine, Flunarizine may increase the bradycardic activities of Lanreotide.]
[N06AB03, fluoxetine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Lanreotide.]
[N05AG01, fluspirilene, Fluspirilene may increase the bradycardic activities of Lanreotide.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Lanreotide.]
[N06DA04, galantamine, Galantamine may increase the bradycardic activities of Lanreotide.]
[C08DA02, gallopamil, Lanreotide may increase the bradycardic activities of Gallopamil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Lanreotide.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Lanreotide.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Lanreotide.]
[N03AD03, methsuximide, Methsuximide may increase the bradycardic activities of Lanreotide.]
[N01AH02, alfentanil, Alfentanil may increase the bradycardic activities of Lanreotide.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Lanreotide.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Lanreotide.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Lanreotide.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the bradycardic activities of Lanreotide.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Lanreotide.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Lanreotide.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Lanreotide.]
[C07AB09, esmolol, Esmolol may increase the bradycardic activities of Lanreotide.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Lanreotide.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin aspart.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Lanreotide.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Lanreotide.]
[C08CA10, nilvadipine, Nilvadipine may increase the bradycardic activities of Lanreotide.]
[M02AA26, nimesulide, Nimesulide may increase the bradycardic activities of Lanreotide.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Lanreotide.]
[N01AH03, sufentanil, Sufentanil may increase the bradycardic activities of Lanreotide.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Lanreotide.]
[M03BX02, tizanidine, Tizanidine may increase the bradycardic activities of Lanreotide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Lanreotide.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Lanreotide.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lanreotide.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Lanreotide.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lanreotide.]
[C07AA01, alprenolol, Alprenolol may increase the bradycardic activities of Lanreotide.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Lanreotide.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Lanreotide.]
[C07AG01, labetalol, Labetalol may increase the bradycardic activities of Lanreotide.]
[N03AX18, lacosamide, Lacosamide may increase the bradycardic activities of Lanreotide.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Lidocaine.]
[C08EX01, lidoflazine, Lanreotide may increase the bradycardic activities of Lidoflazine.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Lanreotide.]
[A07DA03, loperamide, Loperamide may increase the bradycardic activities of Lanreotide.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Lanreotide.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Lanreotide.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the bradycardic activities of Lanreotide.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be decreased when combined with Lanreotide.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Lanreotide.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Mepivacaine.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Lanreotide.]
[C02AB01, methyldopa, Methyldopa may increase the bradycardic activities of Lanreotide.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Lanreotide.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Lanreotide.]
[C07AB02, metoprolol, Metoprolol may increase the bradycardic activities of Lanreotide.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Lanreotide.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Lanreotide.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Lanreotide.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Lanreotide.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Lanreotide.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Lanreotide.]
[C07AA12, nadolol, Nadolol may increase the bradycardic activities of Lanreotide.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Lanreotide.]
[N06AX21, duloxetine, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Lanreotide.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lanreotide.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Lanreotide.]
[N01AH06, remifentanil, Remifentanil may increase the bradycardic activities of Lanreotide.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Lanreotide.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Lanreotide.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Lanreotide.]
[C08CA04, nicardipine, Nicardipine may increase the bradycardic activities of Lanreotide.]
[C08CA05, nifedipine, Nifedipine may increase the bradycardic activities of Lanreotide.]
[C08CA06, nimodipine, Nimodipine may increase the bradycardic activities of Lanreotide.]
[C08CA07, nisoldipine, Nisoldipine may increase the bradycardic activities of Lanreotide.]
[C08CA08, nitrendipine, Nitrendipine may increase the bradycardic activities of Lanreotide.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Lanreotide.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Lanreotide.]
[G02CA02, nylidrin, Nylidrin may increase the bradycardic activities of Lanreotide.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Lanreotide.]
[C07AA02, oxprenolol, Oxprenolol may increase the bradycardic activities of Lanreotide.]
[C07AA23, penbutolol, Penbutolol may increase the bradycardic activities of Lanreotide.]
[N05AG03, penfluridol, Lanreotide may increase the bradycardic activities of Penfluridol.]
[C08EX02, perhexiline, Perhexiline may increase the bradycardic activities of Lanreotide.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Lanreotide.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Lanreotide.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Lanreotide.]
[C08CX01, mibefradil, Mibefradil may increase the bradycardic activities of Lanreotide.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Lanreotide.]
[C07AA03, pindolol, Pindolol may increase the bradycardic activities of Lanreotide.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Lanreotide.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lanreotide.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lanreotide.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin lispro.]
[C07AB01, practolol, Practolol may increase the bradycardic activities of Lanreotide.]
[C01DX02, prenylamine, Prenylamine may increase the bradycardic activities of Lanreotide.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Prilocaine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Procaine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Lanreotide.]
[C01BC03, propafenone, Propafenone may increase the bradycardic activities of Lanreotide.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Lanreotide.]
[C07AA05, propranolol, Propranolol may increase the bradycardic activities of Lanreotide.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Lanreotide.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Lanreotide.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Lanreotide.]
[C07AA07, sotalol, Sotalol may increase the bradycardic activities of Lanreotide.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Lanreotide.]
